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Combination chemotherapy for the treatment of invasive
infections by Scedosporium proli®cans
The saprophytic mold Scedosporium proli¢cans may cause inva-
sive infections in both immunocompromised and immuno-
competent hosts.The recent review byGosbell et al [1] showed
that the outcome of treatment of patients with this infection is
very disappointing, for several reasons.The fungus appears to
disseminate rapidly from the primary site of infection to dis-
tant organs, including the brain.The fungus is able to produce
spores during growth in the tissues, which facilitates dissemi-
nation and explains why this fungus is readily cultured from
the blood [1]. The poor outcome of treatment is also due to
multiresistance of this fungus to the currently available anti-
fungal agents, including amphotericin B, the azoles and £ucy-
tosine. The lack of e¡ective drugs against S. proli¢cans is in
agreement with the in vitro resistance exhibited by this patho-
gen [2], although in vitro results have not yet been correlated
directly with in vivo results. Even novel antifungal agents such
as the triazoles voriconazole, posaconazole and Syn-2869 [2,
3] and the echinocandins LY303366 and caspofungin show
limited or no invitro activity against this fungus [3, 4].
Given the lack of e¡ective antifungal agents, the possibility
of combination therapy should be considered. Although the
authors do not refer to this possibility in their review, there is
some evidence that combinations of antifungals may be e¡ec-
tive against Scedosporium species at least in vitro.The combina-
tion of amphotericin B and azoles was tested against S.
apiospermum, and was additive or synergistic for 67% of the
tested isolates [5]. Furthermore, the combination of terbina-
¢ne with azoles appears to be very active.We have recently
shown synergism between the combinations terbina¢ne^
miconazole and terbina¢ne^itraconazole against S. proli¢cans
[6]. Although terbina¢ne and itraconazole alone appeared to
be inactive against the fungus, pronounced in vitro synergism
was found for 19 of the 20 isolates (95%) after 48  h and for 17
of the 20 isolates (85%) after 72  h of incubation when these
drugs were combined [6]. For three isolates, the combination
appeared to be indi¡erent after 72  h of incubation, and antag-
onismwas not observed.The combination appeared to be also
synergistic against other fungal pathogens, including Candida
albicans [7], Candida glabrata, Cryptococcus neoformans [8], Asper-
gillus fumigatus [9] and Phytium insidiosum [10].
Terbina¢ne is an allylamine, which interacts with the path-
way of ergosterol biosynthesis by inhibiting the conversion of
squalene to 2,3-epoxidesqualene. The activity of the enzyme
squalene epoxidase is impeded by terbina¢ne, which results in
the accumulation of squalene and causes the production of
de¢cient ergosterol.The azoles inhibit a subsequent step in the
biosynthesis of fungal ergosterol by inhibiting the methyla-
tion of lanosterol by 14a-demethylase, a P-450-dependent
enzyme [11]. The interaction of terbina¢ne and azoles with
di¡erent steps of the same pathway of fungal ergosterol bio-
synthesis supports the possibility of synergism.
The in vivo extrapolation of in vitro results is always di¤-
cult, and to date there are very limited animal experimental
data that could support or contradict the observed interaction
in vitro.Terbina¢ne showed relatively little activity in combi-
nation with amphotericin B in a rabbit model of invasive
aspergillosis [12], although antagonism was not observed.
Nevertheless, there are some clinical data that suggest that the
combination terbina¢ne^itraconazole acts synergistically in
vivo. In the ¢rst case, an immunocompetent host su¡ering
from pulmonary pseudallescheriasis (S. apiospermum infection)
was cured after treatment with itraconazole followed by terbi-
na¢ne [13].The patient was treated with itraconazole at a dose
of 400  mg/day for 23  months, but after an initial response the
infection relapsed.Therapy was then changed to terbina¢ne at
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a dose of 500  mg/day, and after 4  months the patient was free
of symptoms.The S. apiospermum isolate was resistant to either
drug alone but susceptible in vitro to the combination [14]. It
was hypothesized that after changing the therapy to terbina-
¢ne, su¤cient levels of itraconazole would be present in the
lungs to allow synergistic interaction with terbina¢ne. In the
second case, a 2-year-old boy developed periorbital cellulitis
due to Pythium insidiosum. A high dose of amphotericin B was
clinically ine¡ective, and combination treatment with itraco-
nazole and terbina¢newas initiated based on the in vitro inter-
action of itraconazole with terbina¢ne against this isolate.The
child responded to this regimen [10].
Although de¢nitive data are lacking with respect to the
clinical e¤cacy of combination therapy for the treatment of
invasive scedosporiosis, the evidence that we have presented
suggests that the combination of an azole with terbina¢ne
should be considered for the treatment of invasive infections
by S. proli¢cans.
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Cerebral infarct and adult respiratory distress syndrome in
a patient with postanginal sepsis
Fusobacterium necrophorum is a virulent anaerobe, most com-
monly associated with pharyngotonsillitis in young adults
and children. Local complications include peritonsillar
abscesses, neck space infections and jugular vein septic throm-
bophlebitis. There may also be metastatic abscesses (most fre-
quently in the lungs, pleural space, liver and large joints)
related to bacteremia (postanginal sepsis or Lemierre syn-
drome) [1^5]. Rarely, retrograde spread of infection causes
cerebral abscess or meningitis. The ¢rst case of adult respira-
tory distress syndrome (ARDS) as a complication of postangi-
nal sepsis was described by Cosgrove et al in 1993 [6]. We
describe an adult patient with postanginal sepsis complicated
byARDS and cerebral infarct, to our knowledge the ¢rst case
in the literature.
The patient had been a healthy 20-year-old female with
no signi¢cant medical history. Seven days prior to admission,
acute pharyngitis was diagnosed and treated with oral ery-
thromycin. A throat culture was negative for b-hemolytic
streptococci.Three days later, she developed bilateral posterior
neck discomfort and sti¡ness and continued having low-grade
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